CAR-T Cell Funding Market Size, Share, By Therapy Type (Tisagenlecleucel-T, Axicabtagene ciloleucel, Brexucabtagene autoleucel, Lisocabtagene maraleucel, Idecabtagene vicleucel, and Ciltacabtagene autoleucel), By Investment Trend (Early-Stage investment, Late-Stage investment, and Strategic investment), By Funding Source Type (Venture Capital, Public Funding, Corporate Investments, and Others), By Application (Acute Lymphoblastic Leukemia (ALL), Ovarian Cancer, Acute Myeloid Leukemia (AML), Rheumatoid Arthritis (RA), and Others), By End-User (Pharmaceutical Companies, Research and Academic Institutions, Contract Research Organizations (CROs), Outpatient Surgery Centers, and Others), and Region (North America, Europe, Asia Pacific, Middle East and Africa, and South America) - Trends, Analysis and Forecast till 2034

CAR-T Cell Funding refers to the financial resources allocated for the research, development, production, and commercialization of Chimeric Antigen Receptor T-cell (CAR-T) therapies. These funds come from various sources, including government grants, private investments, pharmaceutical and biotechnology companies, venture capital, and non-profit organizations.

The funding supports a wide range of activities such as basic research, clinical trials, manufacturing infrastructure, regulatory compliance, and market access initiatives. The primary goal of CAR-T cell funding is to advance the development of these innovative therapies, enhance their efficacy and safety, and ensure they are accessible to patients in need, ultimately aiming to transform cancer treatment and improve patient outcomes.

There are many different players contributing to the CAR-T cell funding landscape. By offering grants and subsidies targeted at promoting innovation and supporting early-stage research, government agencies and public institutions play a crucial role. Significant money inflows are occurring as a result of private investors and venture capital firms realizing the profitable potential of CAR-T therapy. Large biotechnology and pharmaceutical businesses are also making significant investments, whether through strategic alliances and acquisitions or internal development initiatives. Funding efforts are further supported by nonprofit organizations and patient advocacy groups, which emphasize the pressing need to provide these life-saving medications to the market.

Key Drivers of Target Market:

Growth of Venture Capital Investments

• Venture capitalists are showing increased interest in CAR-T cell therapies due to their high market potential. Significant funding is flowing into early-stage companies developing CAR-T cell therapies. The competitive landscape in biotech is driving more venture capital into CAR-T innovations to secure a stake in future market leaders. The potential for high returns on investment in successful CAR-T therapies attracts venture capital.
• For instance, in July 2024, a prominent venture capital firm “Andreesen Horowitz” announced a $300 million fund dedicated to investing in next-generation CAR-T cell therapies, reflecting strong investor confidence.
• The potential for high returns on investment in successful CAR-T therapies attracts venture capital. Expanding networks of investors focused on advanced therapies are increasing funding opportunities.

Pharmaceutical and Biotech Company Investments

• Large pharmaceutical and biotech companies are investing in CAR-T cell research to expand their oncology portfolios. Acquisitions and partnerships with CAR-T cell companies are providing significant funding and resources. Major companies are also investing in developing their own CAR-T cell therapies, driving funding into the sector.
• Also, collaborations between established firms and startups are increasing funding and accelerating development. Increased R&D budgets in the pharmaceutical sector are channeled into CAR-T cell research. Companies are leveraging regulatory incentives to boost investment in CAR-T technologies. For instance, in June 2024, The National Institutes of Health (NIH) announced a $200 million grant for research into advanced cell therapies, including CAR-T cell technologies.

Market Potential and Growth Projections

• The potential market value of CAR-T cell therapies is attracting significant funding from investors looking for high returns. Positive revenue forecasts for CAR-T therapies are driving investor confidence.
• Opportunities for expanding CAR-T therapies into new indications and regions are boosting funding. Early investment in CAR-T technologies provides a competitive advantage in a growing market. Investors are eager to fund innovative technologies that promise substantial market impact.
• Positive clinical outcomes and successful case studies are reinforcing the market potential. Supportive regulatory environments are enhancing market attractiveness and investment.

Restrains:

High Development Costs

• The high cost of research and development for CAR-T cell therapies can deter investors. The complex and expensive manufacturing process adds to overall development costs. The cost of conducting extensive clinical trials for CAR-T therapies is a significant financial burden.

Regulatory and Approval Challenges

• Navigating complex regulatory pathways for CAR-T cell therapies can be challenging and costly. Delays in regulatory approvals can impact timelines and deter investment. Uncertainty in regulatory decisions can affect investor confidence and funding. Variability in regulatory standards across countries can complicate market entry and funding. 

Opportunities:

Rising Emerging Indications

• Developing CAR-T therapies for diseases beyond cancer, such as autoimmune conditions or viral infections, opens new funding avenues. Initiating clinical trials for emerging indications can attract investors interested in pioneering treatments for unmet needs. Early-stage preclinical research into novel indications can secure early funding from investors looking to support cutting-edge science.

Next-Generation CAR-T Technologies

• Investing in CAR-T therapies with improved targeting mechanisms to increase efficacy and reduce off-target effects. Supporting advancements in genetic engineering techniques to enhance CAR-T cell functionality and persistence. Funding research into combining CAR-T cells with other therapeutic modalities, such as checkpoint inhibitors, for synergistic effects. Innovations in cell engineering, such as using CRISPR/Cas9 for precise modifications, can attract funding for next-generation technologies.

Manufacturing and Supply Chain Innovations

• Investing in technologies that lower production costs, such as automated cell processing or novel bioreactor systems. Developing advanced quality control measures to ensure consistent product quality and reliability. Streamlining supply chains to improve efficiency and reduce delays in CAR-T cell manufacturing.

The market is segmented based on Therapy Type, Investment Trend, Funding Source Type, Application, End-User and Region.

Therapy Type Insights:

• Tisagenlecleucel-T: This segment is expected to dominate the target market growth as it is branded as Kymriah, was developed by Novartis and is approved for treating certain types of B-cell lymphomas and acute lymphoblastic leukemia (ALL) in children and young adults. It involves modifying patients' T cells to target CD19, a protein found on the surface of B cells. It was one of the first CAR-T therapies approved, setting the stage for the development of other therapies and establishing a significant market presence.
• Axicabtagene ciloleucel: This segment is known as Yescarta, developed by Kite Pharma (a Gilead company), is approved for treating large B-cell lymphoma and other B-cell malignancies. Its approval for adult patients and its performance in clinical trials have solidified its role in the CAR-T market, driving further research and funding.
• Brexucabtagene autoleucel: This segment is a CD19-targeted CAR-T therapy like Kymriah and Yescarta but optimized for the treatment of MCL. The focus on specific types of lymphoma has prompted investments in developing similar targeted therapies for other indications.

Lisocabtagene maraleucel: This segment is developed by Bristol Myers Squibb, is approved for treating large B-cell lymphoma and other B-cell malignancies. It also targets CD19 but uses a different CAR construct that aims to enhance persistence and efficacy.

• Idecabtagene Vicleucel: This segment targets BCMA (B-cell maturation antigen), which is prevalent on multiple myeloma cells. It marks a significant advancement in CAR-T therapies for multiple myeloma, expanding the range of cancers treated by CAR-T cells.
• Ciltacabtagene Autoleucel: Increased investment in CAR-T technology and upgrades for this category is driven by the competitive landscape and ongoing advancements in multiple myeloma medicines. The introduction of ciltacabtagene autoleucel to the market increases competition in the multiple myeloma market and confirms the effectiveness of CAR-T treatments directed towards BCMA.

Investment Trend Insights:

• Early-Stage Investment: These investments are made at the start of a business or project, frequently in the early stages of CAR-T therapy research, either preclinical or clinical. These often involves seed funding or ‘Series A’ investments to support initial research, technology development, and early clinical trials.
• Late-Stage Investment: This segment is expected to dominate the target market growth as they are made when a CAR-T cell therapy is in advanced clinical stages or has achieved significant milestones, such as late-phase clinical trials or regulatory approvals. These investments carry lower risk compared to early-stage investments due to more mature technologies and data but require larger amounts of capital.
• Strategic Investment: This segment includes strategic partnerships, licensing agreements, or acquisitions aimed at gaining access to CAR-T technologies or expanding therapeutic offerings. It focuses on synergies with existing products, technology platforms, or market strategies to enhance overall business objectives.

Funding Source Type Insights:

• Venture Capital: Funding from venture capital (VC) is essential for new and early-stage businesses creating CAR-T cell treatments. Venture capital firms facilitate the advancement of research and development by offering funding in return for stock to these enterprises. Along with financial support, venture capital often provide strategic guidance, industry connections and operational support to help companies scale and succeed.
• Public Funding: This segment includes government grants and subsidies provided to support research and development in CAR-T cell therapies. This funding often comes from national health organizations, research councils, and specific cancer research initiatives.
• Corporate Investments: This segment is expected to dominate the target market growth as large pharmaceutical and biotechnology companies often invest in CAR-T cell therapies through acquisitions of smaller biotech firms or direct investments in innovative technologies. Corporate investments in CAR-T cell therapies are a component of larger plans to expand into new therapeutic areas and diversify product portfolios.
• Others: This segment includes crowd funding, joint ventures, specialized investment funding, etc. Emerging as a novel funding source, crowd funding platforms allow individuals to contribute to CAR-T cell research and development projects, especially for smaller or niche projects whereas joint ventures between various stakeholders, including public entities, private investors and academic institutions can pool resources for CAR-T cell research and development.

Application Insights:

• Acute Lymphoblastic Leukemia (ALL): This segment is expected to dominate the target market growth as blood cancer known as acute lymphoblastic leukaemia (ALL) attacks the bone marrow and blood. It is distinguished by an excess of immature lymphocytes. Treatment for ALL with CAR-T cell treatments has showed great promise, especially in the case of paediatric and young adult populations. The effectiveness of treatments like tisagenlecleucel, or Kymriah, has resulted in significant financing and investment in this field.
• Ovarian Cancer: This segments originates in the ovaries and is often diagnosed at an advanced stage, making it challenging to treat. It is known for its poor prognosis and high recurrence rate. CAR-T cell therapies are being explored for ovarian cancer to address unmet needs in treatment. Research is focused on identifying appropriate targets and improving efficacy against solid tumors.
• Acute Myeloid Leukemia (AML): This segment is a type of cancer that affects the blood and bone marrow, characterized by the rapid growth of abnormal myeloid cells. AML is challenging to treat due to its heterogeneity and resistance to conventional therapies. CAR-T cell therapies are being developed to target specific antigens present on AML cells.
• Rheumatoid Arthritis (RA): CAR-T cell therapies are being explored for autoimmune diseases like rheumatoid arthritis to modulate the immune system and target specific auto antigens.
• Others: This segment includes various other conditions where CAR-T cell therapies are being investigated, including but not limited to solid tumors for e.g., breast cancer, lung cancer, other hematologic malignancies and rare diseases.

End-User Insights:

• Pharmaceutical Companies: Due to their significant financial resources, ability to undertake extensive clinical trials, and ability to bring medicines to market, pharmaceutical companies dominate the CAR-T Cell Funding Market. They have a comprehensive role in this market, ranging from research to commercialization, which makes them the most significant and powerful category.
• Research and Academic Institutions: Research and academic institutions are at the forefront of discovering new CAR-T cell technologies and therapeutic applications. They conduct early-stage research that lays the foundation for future therapies.
• Contract Research Organizations (CROs): Increasing operational effectiveness, diversifying service offerings, and advancing technology in trial management and data analytics are frequently the goals of funding for CROs. Although CROs are essential to the conduct of clinical trials, they play a more supportive role in the funding market, meeting the demands of research institutions and pharmaceutical corporations.
• Outpatient Surgery Centers: Investments in this segment are directed toward infrastructure improvements, staff training, and compliance with the specialized requirements for administering CAR-T therapies.
• Others: The biotech startups, patient advocacy groups, and regulatory authorities included in this sector have an indirect impact on the financing landscape for CAR-T cells. Biotech startups can introduce disruptive innovations that attract significant investment, while advocacy groups can drive public and private funding through awareness and policy influence.

Regional Insights

• North America: The FDA’s proactive stance on approving CAR-T therapies, along with initiatives like the Breakthrough Therapy Designation, encourages investment. Regulatory clarity and support are key drivers for funding in this region.
• Asia Pacific: Governments in the region are increasingly investing in biotech research and development. China, for instance, has made significant strides in developing CAR-T therapies, supported by substantial government funding.
• Europe: The European Union supports cross-border collaborations and research initiatives through programs like Horizon Europe, which encourages investment in CAR-T cell therapies. The European Medicines Agency (EMA) provides a structured regulatory pathway for advanced therapies, which helps attract funding.
• Latin America: While government programs are starting to fund biotech research in several Latin American countries, the degree of investment and advancement differs greatly amongst them.
• Middle East and Africa: This region is making significant investments in its healthcare infrastructure, which may open doors for the creation and uptake of CAR-T therapies, especially in more developed nations.

CAR-T Cell Funding Market Report Scope:

Attribute	Details
Base year for estimation	2023
Forecast period	2024 – 2034
Market representation	Revenue in USD Million & CAGR from 2024 to 2034
Market Segmentation	By Therapy Type - Tisagenlecleucel-T, Axicabtagene ciloleucel, Brexucabtagene autoleucel, Lisocabtagene maraleucel, Idecabtagene vicleucel, and Ciltacabtagene autoleucel By Investment Trend - Early-Stage investment, Late-Stage investment, and Strategic investment By Funding Source Type - Venture Capital, Public Funding, Corporate Investments, and Others By Application - Acute Lymphoblastic Leukemia (ALL), Ovarian Cancer, Acute Myeloid Leukemia (AML), Rheumatoid Arthritis (RA), and Others By End-User - Pharmaceutical Companies, Research and Academic Institutions, Contract Research Organizations (CROs), Outpatient Surgery Centers, and Others
Regional scope	North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034. For the purpose of this study segmented the target market report based on Therapy Type, Investment Trend, Funding Source Type, Application, End-User, and Region.

By Therapy Type:

• Tisagenlecleucel-T
• Axicabtagene ciloleucel
• Brexucabtagene autoleucel
• Lisocabtagene maraleucel
• Idecabtagene vicleucel
• Ciltacabtagene autoleucel

By Investment Trend:

• Early-Stage investment
• Late-Stage investment
• Strategic investment

By Funding Source Type:

• Venture Capital
• Public Funding
• Corporate Investments
• Others

By Application:

• Acute Lymphoblastic Leukemia (ALL)
• Ovarian Cancer
• Acute Myeloid Leukemia (AML)
• Rheumatoid Arthritis (RA)
• Others

By End-User:

• Pharmaceutical Companies
• Research and Academic Institutions
• Contract Research Organizations (CROs)
• Outpatient Surgery Centers
• Others

By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

The key players operating the CAR-T Cell Funding Market include Gilead Sciences, Inc., Novartis AG, Bristol-Myers Squibb Company, Johnson & Johnson, Bluebird Bio, Inc., Kite Pharma, Inc., Celgene Corporation, AbbVie Inc., Adaptimmune Therapeutics plc, Tessa Therapeutics, Celyad Oncology SA, Autolus Therapeutics plc, Legend Biotech Corporation, Sorrento Therapeutics, Inc., and Iovance Biotherapeutics, Inc.

• In July 2024, The Multiple Myeloma Research Foundation (MMRF) has invested $1 million in Dynamic Cell Therapies (DCT)'s cutting-edge CAR T-cell technology in an effort to improve the treatment of multiple myeloma through its Myeloma Investment Fund. Backed by this investment, DCT remains on track to move a new CAR T-cell therapy into clinical testing in people with relapsed and refractory multiple myeloma over the next few years.

• Gilead Sciences, Inc.*
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Novartis AG
• Bristol-Myers Squibb Company
• Johnson & Johnson
• Bluebird Bio, Inc.
• Kite Pharma, Inc.
• Celgene Corporation
• AbbVie Inc.
• Adaptimmune Therapeutics plc
• Tessa Therapeutics
• Celyad Oncology SA
• Autolus Therapeutics plc
• Legend Biotech Corporation
• Sorrento Therapeutics, Inc.
• Iovance Biotherapeutics, Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Research Objective and Assumption

• Research Objectives
• Assumptions
• Abbreviations

Market Preview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Therapy Type
  • Market Snippet, By Investment Trend
  • Market Snippet, By Funding Source Type
  • Market Snippet, By Application
  • Market Snippet, By End-User
  • Market Snippet, By Region
• Opportunity Map Analysis

Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Market Trends
• Product Launch
• Merger and Acquisitions
• Impact Analysis
• PEST Analysis
• Porter’s Analysis

Market Segmentation, Therapy Type, Forecast Period up to 10 Years, (US$ Bn)

• Overview
  • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Tisagenlecleucel-T
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Axicabtagene ciloleucel
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends
• Brexucabtagene autoleucel
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends
• Lisocabtagene maraleucel
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends

• Idecabtagene vicleucel
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends
• Ciltacabtagene autoleucel
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends

Market Segmentation, Investment Trend, Forecast Period up to 10 Years, (US$ Bn)

• Overview
  • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Early-Stage Investment
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Late-Stage investment
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Strategic investment
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Market Segmentation, Funding Source Type, Forecast Period up to 10 Years, (US$ Bn)

• Overview
  • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Venture Capital
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Public Funding
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Corporate Investments
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

• Others
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Market Segmentation, Application, Forecast Period up to 10 Years, (US$ Bn)

• Overview
  • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Acute Lymphoblastic Leukemia (ALL)
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Ovarian Cancer
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Acute Myeloid Leukemia (AML)
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

• Rheumatoid Arthritis (RA)
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Others
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Market Segmentation, End-User, Forecast Period up to 10 Years, (US$ Bn)

• Overview
  • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Pharmaceutical Companies
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Research and Academic Institutions
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Contract Research Organizations (CROs)
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Outpatient Surgery Centers
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Others
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Market Segmentation, By Region, Forecast Period up to 10 Years, (US$ Bn)

• Overview
  • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Regional Trends
• North America
  • Market Size and Forecast (US$ Bn), By Therapy Type, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Investment Trend, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Funding Source Type, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Application, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By End-User, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
    • U.S
    • Canada
• Asia Pacific
  • Market Size and Forecast (US$ Bn), By Therapy Type, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Investment Trend, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Funding Source Type, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Application, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By End-User, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
    • India
    • Japan
    • South Korea
    • China
    • Rest of Asia Pacific
• Europe
  • Market Size and Forecast (US$ Bn), By Therapy Type, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Investment Trend, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Funding Source Type, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Application, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By End-User, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
    • UK
    • Germany
    • France
    • Russia
    • Italy
    • Rest of Europe
• Latin America
  • Market Size and Forecast (US$ Bn), By Therapy Type, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Investment Trend, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Funding Source Type, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Application, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By End-User, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
    • Brazil
    • Mexico
    • Rest of Latin America
• Middle East and Africa
  • Market Size and Forecast (US$ Bn), By Therapy Type, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Investment Trend, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Funding Source Type, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Application, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By End-User, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
    • GCC
    • Israel
    • South Africa
    • Rest of Middle East and Africa

Competitive Landscape

• Heat Map Analysis
• Company Profiles

• Gilead Sciences, Inc.
• Novartis AG
• Bristol-Myers Squibb Company
• Johnson & Johnson
• Bluebird Bio, Inc.
• Kite Pharma, Inc.
• Celgene Corporation
• AbbVie Inc.
• Adaptimmune Therapeutics plc.
• Tessa Therapeutics
• Celyad Oncology SA
• Autolus Therapeutics plc.
• Legend Biotech Corporation
• Sorrento Therapeutics, Inc.
• Iovance Biotherapeutics, Inc.

The Last Word

• Future Impact
• About Us
• Contact